ALBERT DAVID Latest Share Price (ALBERTDAVD)
TODAY IN ONE LINE
ALBERTDAVD fell 1.1% on average volume, lagging Nifty's 0.1% move.
With a market cap of ₹492.53 Cr., it trades at a P/E of 20.47. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
ALBERT DAVID flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●High Promoter HoldingPromoters hold 62.2% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.07x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Sales ContractionQuarterly sales dropped 69.6% YoY
- ●Rising Receivables vs SalesReceivables grew 10.8% outpacing sales growth of -4.6%
Latest ALBERT DAVID News
What changed recently?
Recent events, corporate actions, and announcements.
ALBERT DAVID valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for ALBERT DAVID, framed against the sector median so the premium or discount is obvious at a glance.
ALBERT DAVID trades at a P/E of 20.47× and P/B of 1.18×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
ALBERT DAVID technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for ALBERT DAVID — derived from the latest tape, not yesterday's close.
ALBERT DAVID last traded at ₹860.25 with an intraday range of ₹851.6–₹878 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹860.25| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 927.77 | +67.52 | +7.85% |
| R3 | 901.37 | +41.12 | +4.78% |
| R2 | 889.68 | +29.43 | +3.42% |
| R1 | 874.97 | +14.72 | +1.71% |
| PIVOT | 863.28 | 3.03 | 0.35% |
| CURRENT | 860.25 | — | — |
| S1 | 848.57 | -11.68 | -1.36% |
| S2 | 836.88 | -23.37 | -2.72% |
| S3 | 822.17 | -38.08 | -4.43% |
| S4 | 795.77 | -64.48 | -7.50% |
ALBERTDAVD is trading Below CPR, indicating Bearishness
CPR is Average
Day's range: ₹876.9–₹876.9
Trading Below opening range, showing Bearishness
ALBERT DAVID financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for ALBERT DAVID — consolidated or standalone — with margins, YoY growth and key ratios inline.
ALBERT DAVID reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹492.53 Cr. and reported EPS of ₹56.07.
ALBERT DAVID segment analysis : revenue and profit mix.
Disclosed business segments at ALBERT DAVID with their share of revenue and profit, switchable between consolidated and standalone reporting.
ALBERT DAVID discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for ALBERT DAVID.
Our AI distills the core fundamental drivers supporting ALBERT DAVID, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
ALBERT DAVID's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Promoter holding 62.24% demonstrates strong founder commitment and operational stability.
Fortress-like capital structure with debt-to-equity ratio 0.0007x, minimal financial leverage.
Substantial cash and short-term investments ₹2,883.42 Cr provide significant operational flexibility.
Diversified pharmaceutical portfolio spanning parenterals, oral, topical, herbal, bulk drugs.
International export presence across Latin America, Southeast Asia, and Africa markets.
Key Risks.
Latest quarterly EPS declined 107% YoY; net profit fell ₹21.4 Cr despite ₹85.9 Cr sales.
Operating margin collapsed to 0.95%, severely compressed versus peer median ~19%.
Negative annual EPS ₹-2.63 indicates persistent earnings destruction for shareholders.
ROE -0.38% and ROCE -2.14% show severely inefficient capital deployment versus peers.
Operating cash flow negative ₹208.45 Cr in latest quarter, signaling acute liquidity strain.
Flip Conditions.
Valuation risk. a P/E above 27 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Income thesis breaks if the dividend is cut or yield falls below 0.29%.
ALBERT DAVID peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — ALBERT DAVID is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
ALBERT DAVID chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for ALBERT DAVID — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
ALBERT DAVID delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for ALBERT DAVID over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in ALBERT DAVID stood at 78.5% of traded volume, against a 20-day average of 64.3%.
ALBERT DAVID announcements: results, concalls, ratings, M&A.
Filings ALBERT DAVID sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
ALBERT DAVID files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 71 documents below.
Shareholders meeting
Albert David Limited has informed the Exchange with copy of minutes of Annual General Meeting held on August 06, 2026
Shareholders meeting
Albert David Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on August 06, 2026. Further, the company…
Copy of Newspaper Publication
Albert David Limited has informed the Exchange about Copy of Newspaper Publication
Shareholders meeting
Albert David Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 06, 2026
Resignation of Director/KMP/SMP
Albert David Limited has informed the Exchange about Resignation of Director/KMP/SMP
Investor decks & rating reports.
ALBERT DAVID dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue ALBERT DAVID has declared, sequenced by announce and record date.
ALBERT DAVID corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
ALBERT DAVID insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in ALBERT DAVID as reported to SEBI — buying and selling signals from the people who know the business best.
ALBERT DAVID insider activity below tracks 1 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| KOTHARI PHYTOCHEMICALS & INDUSTRIES LIMITED | Insider | 24 Feb 2025 | buy | +6.0 K | ₹53.77 L | ₹896.09 |
About ALBERT DAVID: business, sector, key facts.
What ALBERT DAVID does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
ALBERT DAVID operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: ALBERTDAVD, BSE: 524075.
Albert David Limited is a pharmaceutical company based in Kolkata, India, with a long history dating back to its incorporation in 1938. The company's core business centers around the manufacturing and trading of a diverse range of pharmaceutical products within the Indian market and for export.
Their manufacturing capabilities span several key areas within the pharmaceutical industry. They produce a wide variety of formulations, including parenteral (injectable) medications, oral and enteral (through the digestive system) drugs, topical applications for external use, and products specifically designed for vision care. This broad product portfolio allows them to cater to a wide spectrum of patient needs and healthcare applications.
Beyond formulations, Albert David Limited also engages in the production and sale of herbal dosage forms, reflecting a commitment to both traditional and modern medicinal approaches. Furthermore, they are involved in the manufacturing of bulk drugs, which serve as raw materials for the pharmaceutical industry as a whole. This vertical integration, from bulk drug production to finished formulations, provides greater control over the supply chain and quality assurance.
The company's reach extends beyond the domestic Indian market. Albert David Limited actively exports its pharmaceutical products to a variety of international destinations, including countries in Latin America, Southeast Asia, and Africa. This international presence demonstrates their capacity to meet global demand and highlights their competitiveness in the international pharmaceutical arena.
In summary, Albert David Limited is a well-established Indian pharmaceutical company with a diversified product portfolio, encompassing various dosage forms and therapeutic areas. Their manufacturing capabilities extend from bulk drug production to finished formulations, and their market reach spans both domestic and international markets, making them a significant player within the Indian and global pharmaceutical landscape.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about ALBERT DAVID (ALBERTDAVD).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of ALBERT DAVID (ALBERTDAVD)?
The current share price of ALBERT DAVID (ALBERTDAVD) is ₹860.25. Today, the stock has declined by ₹9.90 (1.14%), trading in a range of ₹851.60 to ₹878.00. The stock opened at ₹876.90 with a trading volume of 3,339 shares.
02Is ALBERT DAVID stock a good investment for long-term?
ALBERT DAVID can be considered for long-term investment based on several factors. The company has a market capitalization of ₹492.53 Cr., P/E ratio of 20.47, ROE of -0.38%, and ROCE of -2.14%. The dividend yield stands at 0.58%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of ALBERT DAVID stock?
The 52-week high price of ALBERT DAVID (ALBERTDAVD) is ₹931.85, while the 52-week low is ₹579.90. Currently trading at ₹860.25, the stock is 48.34% above its 52-week low and 7.68% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy ALBERT DAVID stock at the current price?
Whether to buy ALBERT DAVID stock at ₹860.25 depends on multiple factors. The stock is currently trading with a P/E ratio of 20.47 and P/B ratio of 1.18. Today's performance shows a loss of 1.14%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of ALBERT DAVID and when is the next dividend?
ALBERT DAVID offers a dividend yield of 0.58%, which means for every ₹100 invested at the current price of ₹860.25, you can expect to receive approximately ₹0.58 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of ALBERT DAVID?
ALBERT DAVID's key financial metrics include: P/E Ratio: 20.47, P/B Ratio: 1.18, ROE: -0.38%, ROCE: -2.14%, Dividend Yield: 0.58%, EPS: ₹56.07, Book Value: ₹686.04, and Debt-to-Equity: 0.07. The company's market cap stands at ₹492.53 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is ALBERT DAVID stock performing today in the market?
ALBERT DAVID stock opened at ₹876.90 and is currently trading at ₹860.25, showing a decline of ₹9.90 (1.14%). The intraday high is ₹878.00 and low is ₹851.60. The trading volume stands at 3,339 shares, indicating moderate market participation today.
08What is the P/E ratio of ALBERT DAVID and what does it indicate?
ALBERT DAVID has a Price-to-Earnings (P/E) ratio of 20.47, which means investors are willing to pay 20.47 for every ₹1 of earnings. With an EPS of ₹56.07, this P/E ratio indicates moderate valuation in line with market standards. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about ALBERT DAVID (ALBERTDAVD) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.